(Q43195076)

English

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

scientific article published on 14 January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 November 2017

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone (English)

1 reference

Europe PubMed Central

15 November 2017

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

author name string

H Avet-Loiseau

1

1 reference

Europe PubMed Central

15 November 2017

J Soulier

2

1 reference

Europe PubMed Central

15 November 2017

J-P Fermand

3

1 reference

Europe PubMed Central

15 November 2017

I Yakoub-Agha

4

1 reference

Europe PubMed Central

15 November 2017

M Attal

5

1 reference

Europe PubMed Central

15 November 2017

C Hulin

6

1 reference

Europe PubMed Central

15 November 2017

L Garderet

7

1 reference

Europe PubMed Central

15 November 2017

K Belhadj

8

1 reference

Europe PubMed Central

15 November 2017

V Dorvaux

9

1 reference

Europe PubMed Central

15 November 2017

S Minvielle

10

1 reference

Europe PubMed Central

15 November 2017

P Moreau

11

1 reference

Europe PubMed Central

15 November 2017

IFM and MAG groups

12

1 reference

Europe PubMed Central

15 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 January 2010

1 reference

Europe PubMed Central

15 November 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

15 November 2017

24

1 reference

Europe PubMed Central

15 November 2017

623-628

1 reference

Europe PubMed Central

15 November 2017

3

1 reference

Europe PubMed Central

15 November 2017

https://scigraph.springernature.com/pub.10.1038/leu.2009.273

0 references

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Epidemiology and outcomes research for MGUS, myeloma and amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Clinical and biologic implications of recurrent genomic aberrations in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

21 January 2018

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.273

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.273

1 reference

Europe PubMed Central

15 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43195076&oldid=1983601012"